Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, announced today the completion of enrollment for its APL-1202 Phase Ib trial in the US. This new...
Clinical investigators will study the safety and efficacy of this microvascular device designed to restore blood flow and reduce amputations resulting from below the knee peripheral artery disease Micro Medical Solutions (MMS), an innovator in the field of...
trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered NK92 cells in trials: CD16 targeted haNK, CD19/CD16 targeted t-haNK and now...
Safety data from all patients show that KB103 was well tolerated with no adverse events reported Five out of six wounds treated with KB103 in the Phase 2 trial closed 100% during the trial The average time to complete 100% wound closure on KB103 treated wounds in...
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Company has reached alignment with the...
– Approach informed by regulatory guidance and real-world clinical experience – Horizon Therapeutics plc (HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy...
Email
Text